UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 15, 2023

Ocuphire Pharma, Inc.

(Exact name of registrant as specified in its charter)

001-34079

11-3516358

Delaware (State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

37000 Grand River Avenue, Suite 120 Farmington Hills, MI 48335 (Address of principal executive offices and zip code)

248-957-9024

(Registrant's telephone number including area code)

(Registrant's former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	OCUP	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On May 15, 2023, Ocuphire Pharma, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On May 15, 2023, the Company posted an updated corporate presentation to its website at https://ir.ocuphire.com/presentations, which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report.

The information in this Report, including Exhibit 99.2 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Exhibit 99.2 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.2 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit	
Number	Exhibit Description
99.1	Press Release by Ocuphire Pharma, Inc., dated May 15, 2023
<u>99.2</u>	Corporate Presentation, dated May 15, 2023
104	Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OCUPHIRE PHARMA, INC.

By: /s/ Richard J. Rodgers

Richard J. Rodgers Interim President and Chief Executive Officer

Date: May 15, 2023



Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR)

PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis (RM) Set for September 28, 2023; Nyxol Development and Commercialization Funded by Viatris

Cash Balance of \$39 Million Expected to Fund Operations into 2025

FARMINGTON HILLS, Mich., May 15, 2023 – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.

"Ocuphire made significant progress across both our APX3330 and Nyxol programs throughout the first quarter," said Rick Rodgers, Interim Chief Executive Officer. "Based on the efficacy and safety data from the ZETA-1 Phase 2 trial of APX3330, we are preparing for an End-of-Phase 2 meeting with the FDA to confirm Phase 3 registration endpoints and study parameters. If approved, APX3330 has the potential to be a non-invasive, oral, early intervention treatment for millions of DR patients at risk of progressing to vision-threatening complications. For Nyxol, we look forward to the September 2023 PDUFA date in its first indication in RM. With a strong cash position and our partner Viatris funding the Nyxol program, we are well positioned to advance both APX3330 and Nyxol programs."

Key Anticipated Future Milestones

- APX3330: End of Phase 2 meeting with FDA to confirm Phase 3 regulatory path for Oral APX3330 in DR (2H 2023)
- Nyxol: PDUFA date for Nyxol in RM.FDA approval in RM would trigger a \$10 million milestone payment to Ocuphire(September 28, 2023)
- Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia (Late 2023)

Recent Business Highlights

Clinical and Regulatory Updates

- In January 2023, the Company announced topline results from the ZETA-1 Phase 2 trial of oral APX3330 for the treatment of diabetic retinopathy (DR). Oral APX3330 achieved statistical significance on a key pre-specified secondary endpoint of binocular ≥ 3-step worsening of DRSS and demonstrated favorable safety and tolerability. This binocular secondary endpoint is a potential Phase 3 registration endpoint. The Company plans an End-of-Phase 2 FDA meeting in the second half of 2023 to formally confirm this endpoint and other clinical trial parameters.
- In February 2023, the Company announced that the FDA has accepted for review a New Drug Application (NDA) for Nyxol[®] in RM and set a PDUFA date of September 28, 2023. FDA approval in RM would trigger a \$10 million milestone payment to Ocuphire.
- Topline results from the VEGA-2 Phase 3 pivotal trial of Nyxol in presbyopia are expected in late 2023. Nyxol clinical programs in presbyopia and dim light disturbances (DLD) continue to progress as planned.

Presentations, Publications, and Conferences

- From January 2023 through May 2023, several papers, posters, and panel talks were presented at medical and industry conferences with updates on APX3330 in DR and Nyxol in RM, DLD and presbyopia. Highlights include:
 - Results from ZETA-1 Phase 2 trial of APX3330 in DR were presented for the first time to the medical community at the 2th Angiogenesis, Exudation, and Degeneration 2023 Meeting in February 2023.
 - Results from LYNX-1 Phase 3 trial of Nyxol in DLD were presented for the first time to the medical community at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in April 2023, and at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in May 2023.
 - Previously announced results from ZETA-1 Phase 2 trial of APX3330 in DR were presented to the medical community at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in May 2023.

Corporate

In April, Ocuphire announced the appointment of Rick Rodgers as Interim President and Chief Executive Officer. Mr. Rodgers is a seasoned operating executive with 20 years of experience in biopharmaceutical management.

First Quarter ended March 31, 2023 Financial Highlights

As of March 31, 2023, Ocuphire had cash and cash equivalents of approximately \$39.0 million. The Company has no debt. Based on current projections, management believes the present cash on hand will be sufficient to fund operations into 2025.

License and collaborations revenue was \$1.7 million for the three months ended March 31, 2023. There was no revenue recorded in the three months ended March 31, 2022. Revenue during the first quarter of 2023 was derived from the reimbursement of research and development services under the Nyxol License Agreement.

General and administrative expenses for the three months ended March 31, 2023 were \$2.3 million, compared to \$1.7 million for the three months ended March 31, 2022. The increase was primarily attributable to an increase in stock-based compensation, professional services fees, legal support, and business development activities, offset in part by a decrease in payroll and insurance costs on a net basis. General and administrative expenses included \$0.5 million and \$0.3 million in stock-based compensation expense during the three months ended March 31, 2023, and 2022, respectively.

Research and development expenses for the three months ended March 31, 2023 were \$5.6 million, compared to \$4.8 million for the three months ended March 31, 2022. The increase was primarily attributable to increased manufacturing activities for Nyxol and APX3330 period over period as well as increased payroll and consulting costs during the current period. Research and development expenses also included \$0.3 million and \$0.1 million in stock-based compensation expense during the three months ended March 31, 2023, and 2022, respectively.

The loss from operations for the quarter ended March 31, 2023 was \$6.1 million, compared to \$6.5 million for the quarter ended March 31, 2022.

Net loss for the quarter ended March 31, 2023 was \$5.8 million or (\$0.28) per share, compared to \$6.6 million or (\$0.35) per share for the quarter ended March 31, 2022.

For further details on Ocuphire's financial results, refer to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 to be filed with the Securities and Exchange Commission.

About Ocuphire Pharma

Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders.

Ocuphire's lead product candidate targeting retinal (back-of-the-eye) indications APX3330, is a first-in-class, small molecule oral drug that blocks downstream pathways regulated by transcription factor Ref-1 – including those involving angiogenesis (VEGF) and inflammation (NFkB). These pathways are implicated across several ocular diseases, including diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD). Ocuphire recently announced topline data from the ZETA-1 Phase 2 trial in which APX3330 achieved statistical significance on a key pre-specified secondary endpoint of preventing clinically meaningful progression of DR after 24 weeks of daily treatment. APX3330 has also shown a favorable safety and tolerability profile in diabetic subjects (ZETA-1 trial) and in 11 previous clinical trials conducted in healthy, liver disease, and cancer subjects. An End-of-Phase 2 meeting with the FDA is planned for APX3330.

Ocuphire has a partnership with Viatris, Inc. to develop and commercialize Nyxo[®] eye drops as a preservative-free eye drop formulation of phentolamine mesylate, a nonselective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size by uniquely blocking the alpha-1 receptors found only on the iris dilator muscle without affecting the ciliary muscle. Nyxol has been studied in a total of 12 clinical trials (3 Phase 1, 5 Phase 2, 4 Phase 3) across three indications, including single-use for reversal of pharmacologically-induced mydriasis (RM), and once-daily for treatment of presbyopia and dim light (night) vision disturbances (DLD), pending regulatory approvals. Nyxol's NDA under the 505(b)(2) pathway for the first indication, RM, has been accepted with a PDUFA date assigned of September 28, 2023. Nyxol is currently in Phase 3 for presbyopia and DLD.

For more information, visit www.ocuphire.com

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the timing and success of identifying a permanent CEO, the potential receipt of regulatory approval for Nyxol for the treatment of RM, expected financial results for the quarter ended March 31, 2023, the ability to fund operations into 2025, the occurrence and timing of an End-of-Phase 2 meeting with the FDA, the ability of Viatris to execute successful US and global launches of Nyxol, and the ability to determine a path to registration for APX3330. These forward-looking statements are based upon Ocuphire's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations; (ix) risks that the Nyxol partnership may not facilitate the commercialization or market acceptance of Ocuphire's product candidates; (x) the success and timing of commercialization of any of Ocuphire's product candidates; and (xi) the maintenance of Ocuphire's intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Corporate	Investor Relations			
Rick Rodgers	Corey Davis, Ph.D.	Bret Shapiro		
Interim President & CEO	LifeSci Advisors	CoreIR		
<u>ir@ocuphire.com</u>	cdavis@lifesciadvisors.com	<u>brets@coreir.com</u>		

Ocuphire Pharma, Inc. Condensed Balance Sheets (in thousands, except share amounts and par value)

		As of		
		arch 31, 2023 naudited)	Ι	December 31, 2022
Assets				
Current assets:				
Cash and cash equivalents	\$	38,988	\$	42,634
Accounts receivable		2,834		1,298
Contract asset		2,467		3,552
Prepaids and other current assets		1,088		1,453
Short-term investments		22		49
Total current assets		45,399		48,986
Property and equipment, net		5		6
Total assets	\$	45,404	\$	48,992
Liabilities and stockholders' equity				
Current liabilities:				
Accounts payable	\$	2,221	\$	1,069
Accrued expenses		1,933		1,684
Total current liabilities		4,154		2,753
Warrant liabilities		_		_
Total liabilities		4,154		2,753
Commitments and contingencies				
Stockholders' equity				
Preferred stock, par value \$0.0001; 10,000,000 shares authorized as of March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022.	l	_		_
Common stock, par value \$0.0001; 75,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 20,947,830 and 20,861,315 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively.		2		2
Additional paid-in capital		118,519		117,717
Accumulated deficit		(77,271)		(71,480
Total stockholders' equity		41,250	_	46,239
Total liabilities and stockholders' equity	\$	45,404	\$	48,992

Ocuphire Pharma, Inc. Condensed Statements of Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited)

	1	onths Ended rch 31,
	2023	2022
License and collaborations revenue	<u>\$ 1,749</u>	<u>\$ </u>
Operating expenses:		
General and administrative	2,285	1,736
Research and development	5,595	4,772
Total operating expenses	7,880	6,508
Loss from operations	(6,131) (6,508)
Interest expense		(5)
Fair value change in warrant liabilities	_	·
Other income (expense), net	340	(82)
Loss before income taxes	(5,791) (6,595)
Benefit (provision) for income taxes		
Net loss	(5,791) (6,595)
Other comprehensive loss, net of tax		
Comprehensive loss	<u>\$</u> (5,791) <u>\$ (6,595</u>)
Net loss per share:		
Basic and diluted	\$ (0.28) <u>\$ (0.35</u>)
Number of shares used in per share calculations:		
Basic and diluted	20,939,607	18,888,471



Disclosures and Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the success and timing of planned regulatory filings and approvals, pre-commercial activities, commercialization strategy and timelines, business strategy, product labels, cash runway, scalability, future clinical trials in presbyopia (P), dim light/night vision disturbance (DLD) and diabetic retinopathy (DR) / diabetic macular edema (DME), including the potential for Nyxol to be a "best in class" presbyopia drop, and timing of planned future clinical trials for APX330, the success and timing of planned regulatory filings, business strategy, cash runway, scalability, the potential of a Phase 3 registration path for APX3330, the success and timing of planned regulatory filings, business strategy, cash runway, scalability, the potential for APX330 to be the first line of therapy for DR patients, and the potential market opportunity for the slowing of DR progression. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success, costs, and timing of regulatory submissions and pre-clinical and clinical trials, including programs; (vi) legislative, regulatory, political and economic developments; (ii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire's product candidates; (ix) the success and timing of commercialization of any of Ocuphire's product candidates (ix) the success and timing of commercialization of any of Ocuphire's product candidates; (ix) the succes and timing of commercialization of any o

The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained in or incorporated by reference into this presentation is, or shall be relied upon as, a promise or representation by the Company as to the past or future. The Company assumes no responsibility for the accuracy or completeness of any such information. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.



Corporate Highlights

		ge Novel Drugs Addressing Multiple Large C Extensive Patent Portfolio	phthalmology Markets with Limited
	APX3330 oral tablets Diabetic Retinopathy/Diabetic Macular Edema (DR/DME)	Nyxol eyedrops Reversal of Mydriasis (RM) – eye dilation Presbyopia (P) – age-related blurry near vision Dim Light or Night Vision Disturbances (DLD)	
	Global License Agreer All Indications	nent with Viatris to Fund the Development ar	nd Commercialization of Nyxol for
(JS)	APX3330 – Paradigm	Changing Oral Tablet for 8 million DR patien	ts; Moving into Phase 3
	Nyxol for RM Indication	n PDUFA Date on September 28, 2023	
	Strong Financial Positi	on to Advance APX 3330 and Nyxol Clinical	Programs into 2025
Ocuphi	re		

Ocuphire Pipeline

Product Candidate	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Regulatory Approval		Upcoming Milestones
APX3330 Oral Pill	Diabetic Retinopathy (DR)/ Macular Edema (DME)				EOP2 Meeting			EOP2 Mtg 2H 2023 to Advance to Phase 3
Nyxol® Eye Drop	Reversal of Mydriasis (RM)			Partnered	with Viatris	PDUFA Sept 28, 2023		PDUFA Date Sep 28, 2023
Nyxol® Eye Drop					Ph3			
Nyxol® + 0.4% Low Dose Pilocarpine (LDP) Eye Drops	Presbyopia (P)		Partne	ered with Viatris	Initiated			VEGA-2 Phase 3 Topline Data Late 2023
Nyxol® Eye Drop	Dim Light or Night Vision Disturbances (DLD)			Partnered with '	Viatris		•	LYNX-2 2nd Phase 3 trial (n=150+)

Ocuphire

Global Partnership with Viatris for Nyxol

Viatris Has Selected Nyxol to be a Key Element of its Global Eye Care Division



Partner for Nyxol global commercialization



Fully funded development and commercialization costs for all 3 Nyxol indications



Allows Ocuphire to focus on APX3330 development




Strengthens cash position into 2025

Ocuphire

- > \$35 million upfront
- Funding for potentially all R&D and commercialization for all 3 indications globally
- \$130 million in regulatory and sales milestones
 - First potential \$10 million milestone payment on FDA approval in RM


5

> Tiered double digit royalties through 2040




Diabetic Retinopathy At a Glance

Larger Disease to Manage with Growing Diabetes



DRSS Predicts Vision-Threatening Complications (PDR/DME)






Early treatment diabetic retinopathy study research group, ophthalmology. 1991;98(5 suppl):823-33. Diabetes control and complications trial research group, N Engl J Med. 1993;329(14):997-86. Fathy C, Patel S, Sternberg P Jr, Kohanin S, Disparities in advernence to screening guidelines for diabetic retinopathy in the United States: a comprehensive review and guide for future directions. Semin Ophthalmol. 2016;31(4):364–377. doi: 10.3109/08820538.2016.1154170 1. 2. 3.

8

Broad Opportunities to Treat Retinal Diseases with APX3330



9

APX3330 Profile Overview

Oral, First-In-Class Ref-1 Inhibitor with Favorable Human Safety Data from 12 Completed Trials


MOA and Efficacy Signals in DR	Favorable Safety Profile
Novel MOA for Treating Retina ↓ Inflammation ↓ Abnormal Angiogenesis	Over 350 Subjects (Healthy, Liver, Cancer, Diabetic treated with Several Subjects Systemically Dosed Year and Others at 24-Wks
Good Patient Compliance in ZETA-1 with Convenient Oral Dosing	Few Systemic AEs Across All Doses (120mg-720mg < 5% Mild Skin Rash/Pruritis (reversible) < 5% Mild Diarrhea
APX3330 Demonstrated Slowing of	No Treatment-Related Organ Toxicity
Progression of Diabetic Retinopathy	Minimal Ocular Side Effects*



Source: ZETA-1 Clinical Trial *1 subject had vision blur thought to be related by investigator in ZETA-1

APX3330 Ref-1 Inhibition – Decreases Abnormal Angiogenesis


Ref-1 Involved in Multiple Key Pathways that Contribute to DR and DME




- Ref-1 (reduction-oxidation effector factor-1), a novel target for retinal diseases, is a transcription factor regulator of angiogenesis (VEGF) and inflammation (NFkB)
- Unique dual MOA decreases abnormal angiogenesis and inflammation
- Anti-VEGF injections do not target inflammation
- Previously developed by Eisai for hepatic inflammatory indications and by Apexian for solid tumors in 11 Phase 1 and 2 trials
- Extensively studied in over **20 in-vitro and animal studies** with favorable efficacy and safety

ZETA-1 Phase 2 Design – APX 3330 in DR

Randomized, Double-masked, Placebo-controlled 24-week Trial (Similar to Eylea P3 DR trial)



Change in DRSS is Regulatory Approval Endpoint for DR




ZETA-1: Baseline Characteristics - Well-Balanced Across Arms

DRSS Scores			Key Visual Metrics			
	APX3330 n=51	Placebo n=52		APX3330 n=51	Placebo n=52	Total n=103
DRSS Score – Study Eye			BCVA		70	80
47 (Moderately severe to severe NPDR)	22 (43%)	18 (35%)	Study Eye Letters (mean)	81	78	(20/25 Snellen)
53 (Moderately severe to severe NPDR)	25 (49%)	28 (54%)	BCVA Fellow Eye Letters (mean)	76	77	(20/32 Snellen)
61 (Mild proliferative diabetic retinopathy)	4 (8%)	6 (12%)	OCT CST Study Eye	270	271	271
DRSS Score – Fellow Eye			(μm)			
43 or Lower (Mild to moderate NDPR or better)	14 (31%)	12 (24%)	OCT CST Fellow Eye	292	286	289
47 (Moderately severe to severe NPDR)	13 (29%)	19 (39%)	(µm) Intraretinal Fluid			
53 (Moderately severe to severe NPDR)	12 (27%)	9 (19%)	in the Center of SE	Y – 21 N – 26	Y – 12 N – 31	Y – 33 N – 57
61 (Mild proliferative diabetic retinopathy)	1 (2%)	4 (8%)	Intraretinal Fluid at the Foveal	Y – 1	Y-1	Y-2
65 or Higher (Moderate to severe prolif. DR)	5 (11%)	5 (10%)	Center of SE	N – 20	N – 41	N – 61
Ocuphire Source: ZETA-1 Clinical Trial		es were CST>320 nvolved DME eyes)	Intraocular Pressure in Study Eye (mmHg)	15	16	15

14

Good Visual Acuity Fluid Below 320µm

ZETA-1: % of Subjects with Binocular Improvement/Worsening in DRSS at Wk 24



APX3330 Demonstrated Statistical Efficacy on Potential Phase 3 Registration Endpoint


15

ZETA-1: Percent of Subjects With Binocular ≥ 3-Step Worsening in DRSS

Primary Endpoint for Planned Phase 3 Demonstrates Prevention of Progression

Percent of Subjects With Worsening in DRSS of ≥3 Steps From Baseline by Visit Binocular Eyes (mITT-LOCF)

Percentage of Subjects with ≥ 5 Letters of BCVALost at Week 24 (Safety Population)



ZETA-1: Treatment Emergent Adverse Events

Oral APX3330 Showed a Favorable Safety Profile Consistent with Prior Trials

		APX3330 (n=51)	Placebo (n=52)	Total (n=103)
Ī	Total AEs	91	120	211
	# of Subjects with AEs	29 (57%)	35 (67%)	64 (62%)
	Treatment Related AEs	14 (45%)	17 (55%)	31 (30%)
Ī	Serious AEs	3 (3%)	11 (9%)	14 (7%)
Ī	Subjects Withdrawals Due to AEs	2 (4%)	1 (2%)	3 (3%)
Ī	Deaths	0 (0%)	1 (2%)	1 (1%)
	AEs in >5% of Subjects*			
SIG	Diabetic Retinal Edema	2 (4%)	5 (10%)	7 (7%)
Eye disorders	Diabetic Retinopathy	1 (2%)	6 (12%)	7 (7%)
edis	Vitreous detachment	0 (0%)	3 (6%)	3 (3%)
Щ	Cataract	3 (6%)	1 (2%)	4 (4%)
	Pruritus	6 (12%)	1 (2%)	7 (7%)
	Rash	3 (6%)	1 (2%)	4 (4%)
[COVID-19	1 (2%)	5 (10%)	6 (6%)


APX3330 Safety Profile:


- · Limited AEs, most mild in severity
- AEs similar to or less than placebo (except for pruritis/rash)
- Few serious treatment-related AEs, all unrelated to study medication
- No ocular AEs other than expected DR progression
- No effect on clinical labs
- No adverse effects on heart, kidney, liver, CNS, GI
- No effect on vital signs (HR, BP)
- Patients continued routine medications to manage their diabetes comorbidities




APX3330 SAEs: Dyskinesia, TIA, Chest pain Placebo SAEs: Vertigo, Asthenia, Multiple organ dysfunction, Bradycardia, CAD AEs — WithdrawIAPX330: Presyncope, Dyspnea; Placebo: DME (both eyes) *Preferred Term within Organ Class

APX3330 - Phase 2 Summary and Next Steps





No Engagement of Ciliary Muscle, No Headaches and Lower Risk of Retinal Detachment






Summary of Nyxol Trial Results

Comprehensive Body of Clinical Data Supporting Efficacy and Safety Across 3 Indications

Indication	Primary Endpoint	Efficacy Data	Key Secondary Endpoint(s)	Safety & Tolerability
RM	Return to baseline pupil diameter at 90 minutes after dilation	Met Phase 3 primary endpoint MIRA-3: 58% Nyxol vs. 6% placebo MIRA-2: 49% Nyxol vs. 7% placebo (p<0.0001) MIRA-4: 64% Nyxol vs. 25% placebo	Efficacy across all mydriatic agents, iris color, 1 or 2 drops, and all ages (3-80)	
Presbyopia (Nyxol Alone)	≥3 line gain in near vision	Met planned Phase 3 primary endpoint VEGA-1: 29% Nyxol vs.12% placebo at 12 hrs post-Nyxol dose (p=0.02)	Durable near vision (18 hrs) Optimal pupil size Pupillary light reflex	 No headaches No blurry vision
Presbyopia (Nyxol + LDP)	with loss of no more than 1 line in distance vision	Met Phase 2 primary endpoint Met planned Phase 3 primary endpoint VEGA-1: 61% combo post-LDP dose (30 min) + post-Nyxol dose (12 hrs) vs. 14% placebo (p<0.0001)	Durable near vision gain Optimal pupil size Pupillary light reflex	 ~5% mild redness No change in IOP No SAEs MostAEs were mild
DLD	≥3 lines (eye test) of improvement in mesopic low contrast best-corrected distance visual acuity (mLCVA)	Met Phase 3 primary endpoint LYNX-1: 13% Nyxol vs. 3% placebo at Day 8 (p<0.05) and 21% in Nyxol vs.3% placebo at Day 15 (p<0.01)	Improvement visual acuity measures (distance and near) in dim light conditions	
Ocuphire		(p~0.01)	all arms planned in Phase 3 program	

21

A New, Differentiated MOA and Combination Therapy Offers Tunability



Corporate Websites, Grzybowski, A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. 2020

22

Corporate Highlights

	Two Lead Clinical-Stage Novel Drugs Addressing Multiple Large Ophthalmology Markets with Limit to No Competition & Extensive Patent Portfolio		phthalmology Markets with Limited
	APX3330 oral tablets Diabetic Retinopathy/Diabetic Macular Edema (DR/DME)	Nyxol eyedrops Reversal of Mydriasis (RM) – eye dilation Presbyopia (P) – age-related blurry near vision Dim Light or Night Vision Disturbances (DLD)	
	Global License Agreement with Viatris to Fully Fund the Development and Commercialization of Nyxol for All Indications		
(1)	APX3330 – Paradigm changing oral for 8 million DR patients; Moving into Phase 3		
	Nyxol for RM Indication PDUFA Date on September 28, 2023 Strong Financial Position to Advance APX and Nyxol Clinical Programs into 2025		
Ocuphire			



Management Team with Decades of Drug Development Experience



Ocuphire's World-Class Medical Advisory Board



Ocuphire Board of Directors

Seasoned Directors with Decades of Drug Development, M&A/Financings, and Ophthalmology



Ocuphire